In this study, we retrospectively analyzed the effects of treatment in 19 patients with membranous lupus nephritis (MLN) and nephrotic syndrome, Eight patients were treated with corticosteroids alone, and the other 11 patients received methylprednisolone and chlorambucil alternated every other month for 6 months, At presentation, sex, age, duration of renal disease before renal biopsy, plasma creatinine, and arterial hypertension were similar in the two study groups, Of the eight patients treated with corticosteroids alone, three showed complete remission and one partial remission of the nephrotic syndrome, During the follow-up (mean, 114 +/- 63 months), seven of these eight patients developed one or more renal flare-ups, Of the 11 patients treated with methylprednisolone and chlorambucil, seven had complete remission, and the other four had partial remission of the nephrotic syndrome, During the follow-up (mean, 83 +/- 59 months), only one patient had renal flare-up, At the end of the follow-up, all patients were alive, but three patients in the group treated with corticosteroids alone had developed a doubling of plasma creatinine, and another patient had persistent nephrotic syndrome, Two other patients were in complete remission, one patient was in partial remission, and the last patient had nonnephrotic proteinuria, In the group of patients treated with methylprednisolone and chlorambucil, one patient developed extracapillary glomerulonephritis and eventually entered end-stage renal failure 24 years after the clinical onset of renal disease, Seven patients were in complete remission, and three patients were in partial remission at the last follow-up visit, This retrospective study suggests that methylprednisolone and chlorambucil may induce a more stable remission of nephrotic syndrome and may better protect renal function in the long term in comparison with corticosteroids alone, However, these results must be confirmed by a prospective controlled trial. (C) 1998 by the National Kidney Foundation, Inc.
Treatment of membranous lupus nephritis
Moroni G;
1998-01-01
Abstract
In this study, we retrospectively analyzed the effects of treatment in 19 patients with membranous lupus nephritis (MLN) and nephrotic syndrome, Eight patients were treated with corticosteroids alone, and the other 11 patients received methylprednisolone and chlorambucil alternated every other month for 6 months, At presentation, sex, age, duration of renal disease before renal biopsy, plasma creatinine, and arterial hypertension were similar in the two study groups, Of the eight patients treated with corticosteroids alone, three showed complete remission and one partial remission of the nephrotic syndrome, During the follow-up (mean, 114 +/- 63 months), seven of these eight patients developed one or more renal flare-ups, Of the 11 patients treated with methylprednisolone and chlorambucil, seven had complete remission, and the other four had partial remission of the nephrotic syndrome, During the follow-up (mean, 83 +/- 59 months), only one patient had renal flare-up, At the end of the follow-up, all patients were alive, but three patients in the group treated with corticosteroids alone had developed a doubling of plasma creatinine, and another patient had persistent nephrotic syndrome, Two other patients were in complete remission, one patient was in partial remission, and the last patient had nonnephrotic proteinuria, In the group of patients treated with methylprednisolone and chlorambucil, one patient developed extracapillary glomerulonephritis and eventually entered end-stage renal failure 24 years after the clinical onset of renal disease, Seven patients were in complete remission, and three patients were in partial remission at the last follow-up visit, This retrospective study suggests that methylprednisolone and chlorambucil may induce a more stable remission of nephrotic syndrome and may better protect renal function in the long term in comparison with corticosteroids alone, However, these results must be confirmed by a prospective controlled trial. (C) 1998 by the National Kidney Foundation, Inc.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
